Hydrogen Sulfide Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite in Sepsis-Evoked Acute Lung Injury via Transient Receptor Potential Vanilloid Type 1 Channel Activation

Seah-Fang Ang, Selena W. S. Sio, Shabbir M. Moochhala, Paul A. MacAry and Madhav Bhatia

*J Immunol* published online 28 September 2011
http://www.jimmunol.org/content/early/2011/09/28/jimmunol.1101559

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Hydrogen Sulfide Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite in Sepsis-Evoked Acute Lung Injury via Transient Receptor Potential Vanilloid Type 1 Channel Activation

Seah-Fang Ang,†,‡,§ Selena W. S. Sio,∥ Shabbir M. Moocchala,¶,∥§ Paul A. MacAry,*,†,‡ and Madhav Bhatia∥

Hydrogen sulfide (H$_2$S) has been shown to promote transient receptor potential vanilloid type 1 (TRPV1)-mediated neurogenic inflammation in sepsis and its associated multiple organ failure, including acute lung injury (ALI). Accumulating evidence suggests that the cyclooxygenase-2 (COX-2)/PGE$_2$ pathway plays an important role in augmenting inflammatory immune response in sepsis and respiratory diseases. However, the interactions among H$_2$S, COX-2, and PGE$_2$ in inciting sepsis-evoked ALI remain unknown. Therefore, the aim of this study was to investigate whether H$_2$S would upregulate COX-2 and work in conjunction with it to instigate ALI in a murine model of polymicrobial sepsis. Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in male Swiss mice. α-propargylglycine, an inhibitor of H$_2$S formation, was administered 1 h before or 1 h after CLP, whereas sodium hydrosulfide, an H$_2$S donor, was given during CLP. Mice were treated with TRPV1 antagonist capsazepine 30 min before CLP, followed by assessment of lung COX-2 and PGE$_2$ metabolite (PGEM) levels. Additionally, septic mice were administered with parecoxib, a selective COX-2 inhibitor, 20 min post-CLP and subjected to ALI and survival analysis. H$_2$S augmented COX-2 and PGEM production in sepsis-evoked ALI by a TRPV1 channel-dependent mechanism. COX-2 inhibition with parecoxib attenuated H$_2$S-augmented lung PGEM production, neutrophil infiltration, edema, proinflammatory cytokines, chemokines, and adhesion molecules levels, restored lung histoarchitecture, and protected against CLP-induced lethality. The strong anti-inflammatory and antiseptic actions of selective COX-2 inhibitor may provide a potential therapeutic approach for the management of sepsis and sepsis-associated ALI.

The Journal of Immunology, 2011, 187: 000–000.
a specific COX-2 inhibitor, was found to inhibit PGE2 production of endotoxin-treated macrophages to improve survival and restore leukocyte counts in burn septic mice (13). Similarly, in a rat endotoxin shock model, NS-398 significantly inhibited the heightened COX-2 gene expression and PGE2 production in the aorta and peripheral blood leukocytes (22). Additionally, H2S was shown to induce COX-2 gene and protein expression in human small intestine epithelial FHs 74 cells and isolated rat cardiac myocytes, respectively (23, 24). Despite these findings, describing the inflammatory roles of COX-2 and PGE2 and the interactions among H2S, COX-2, and PGE2 in inciting sepsis-evoked ALI remain unknown. Therefore, the current study aimed to investigate whether H2S can upregulate COX-2 and work in conjunction with it to instigate ALI in sepsis through a TRPV1 channel-dependent mechanism and, if so, to elucidate whether selective COX-2 inhibition attenuates H2S-augmented lung inflammation and injury as well as lethality in sepsis.

Materials and Methods

Animal model of sepsis

All experiments were approved by the Animal Ethics Committee of the National University of Singapore and were conducted in accordance with established International Guiding Principles for Animal Research. A previously described model of cecal ligation and puncture (CLP)-induced sepsis was used (6). Briefly, male Swiss mice, 5 to 6 wk of age (25–30 g), were anesthetized with a mixture of ketamine and medetomidine (7.5 ml/kg i.p.) under aseptic conditions. A 1-cm midline incision was made through the skin and peritoneum of the abdomen. The cecum was exposed, ligated below the ileocecal valve without occluding the bowel passage, and then perforated at two locations with a 22-gauge needle distal to the point of ligation. Then, a small amount of cecal content was squeezed out gently to ensure persistence of the punctures. Finally, the bowel was repositioned, and the abdomen was closed in layers. Animals with sham operation served as controls and underwent the same procedure except that the cecum was neither ligated nor punctured. All mice were resuscitated with 1 ml 0.9% sterile saline (s.c.) immediately after the surgery. Capsazepine (15 mg/kg s.c.; Sigma-Aldrich, St. Louis, MO), a TRPV1 antagonist, or vehicle (DMSO) was administered to mice 30 min before CLP. Parecoxib (30 mg/kg i.v.; Dynastat; Pfizer, New York, NY), a potent and selective COX-2 inhibitor (25–27), or saline was administrated to mice 20 min after CLP. The dosage of capsaicine and parecoxib has been described in the literature and found to be effective in vivo (6, 14). N-propargylglycine (PAG; 50 mg/kg i.p.; Sigma-Aldrich), an irreversible inhibitor of CSE, was administered either 1 h before (prophylactic) or 1 h after (therapeutic) surgery. NaHS (10 mg/kg i.p.; Sigma-Aldrich), an H2S donor, was given to mice during CLP. Animals were killed by a lethal dose of pentobarbitone (30 mg/kg i.v.; Dynastat; Pfizer, New York, NY) (original magnification ×200).

Cytokines, chemokines, and adhesion molecules analysis

Single-analyte ELISA assays were performed for the measurement of cytokines (IL-1β, IL-6, and TNF-α), chemokines (MIP-1α and MIP-2), and adhesion molecules (P-selectin, E-selectin, ICAM-1, and VCAM-1) in homogenized lung tissue, according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN). The lower limits of detection for the single-analyte ELISA kits used (6) were 0.5, 1.6 mM tetrathiomethane-bisulfide (Sigma-Aldrich), 80 mM sodium phosphate buffer (pH 5.4), and 0.3 mM hydrogen peroxide (reagent volume: 50 μl). This mixture was incubated at 37°C for 110 s. The reaction was terminated with 50 μl of 0.18 M H2SO4, and the absorbance was measured at 450 nm. This absorbance was then corrected for the DNA content of the tissue samples (28), and results were expressed as fold increase over control.

H2S AND COX-2/PGE2 PATHWAY IN SEPSIS-EVOKED ALI

Measurement of myeloperoxidase activity

Neutrophil sequestration in lung was quantified by measuring myeloperoxidase (MPO) activity (6). Lung samples were thawed, homogenized in 20 mM phosphate buffer (pH 7.4), centrifuged (13,000 × g, 10 min, 4°C), and the resulting pellet was resuspended in 50 mM phosphate buffer (pH 6) containing 0.5% w/v hexadecyltrimethylammonium bromide (Sigma-Aldrich). The suspension was subjected to four cycles of freezing and thawing and was further disrupted by sonication (40 s). The samples were then centrifuged (13,000 × g, 5 min, 4°C) and the supernatants used for the MPO assay. The reaction mixture consisted of the supernatant (50 μl), 1.6 mM tetrathiomethane-bisulfide (Sigma-Aldrich), 80 mM sodium phosphate buffer (pH 5.4), and 0.3 mM hydrogen peroxide (reagent volume: 50 μl). This mixture was incubated at 37°C for 110 s. The reaction was terminated with 50 μl of 0.18 M H2SO4, and the absorbance was measured at 450 nm. This absorbance was then corrected for the DNA content of the tissue samples (28), and results were expressed as fold increase over control.

Histopathological examination

A small portion of lung was excised and fixed with 10% neutral buffered formalin (Sigma-Aldrich), then subsequently dehydrated through a graded ethanol series, embedded in paraffin wax, and sectioned for routine histology. Sections of 5-μm thickness were stained with H&E and examined by light microscopy using a Carl Zeiss light microscope (Thornwood, New York, NY) (original magnification ×200).

Measurement of pulmonary edema

As an index of lung edema, the amount of extravascular lung water was calculated according to established techniques (29–31). Briefly, mice were killed 8 h after surgery, and blood was collected by cardiac puncture. The lungs were excised from mice, cleared of all extrapulmonary tissue, blotted, and weighed (total lung wet weight); they were then dried in an incubator for 48 h at 80°C and weighed again (total dry weight). For each animal, pulmonary edema was expressed as the ratio of total wet weight to total dry weight.

Survival study

Mortality was monitored for 24 h after sham or CLP procedure. The survival of these mice was recorded for up to 12 d. Mice that survived beyond this time point were considered as permanent survivors.

Statistics

The data were expressed as mean ± SEM. The significance of difference among groups was evaluated by ANOVA with a post hoc Tukey’s test for multiple comparisons when comparing three or more groups. The survival rate was estimated by the Kaplan–Meier method and compared by log-rank test. A p value < 0.05 was regarded as statistically significant.
Results

H$_2$S regulates COX-2 levels in septic lungs in a TRPV1 channel-dependent manner

Induction of sepsis by CLP resulted in a significant increase in lung COX-2 expression as compared with sham-injured mice (Fig. 1A). Administration of NaHS further enhanced pulmonary COX-2 expression in septic mice when compared with their vehicle control counterparts (Fig. 1A). In an attempt to investigate the interplay between H$_2$S and COX-2 with TRPV1-mediated neurogenic inflammation in sepsis, we tested the effect of a selective TRPV1 antagonist, capsazepine, on lung COX-2 levels. Our results revealed marked attenuation in pulmonary COX-2 expression with capsazepine in both septic and septic mice administered with NaHS (Fig. 1A). A similar profile was observed in lung COX-2 activity levels, with septic mice showing significant increase, whereas septic mice injected with NaHS exhibited greater elevation in levels (Fig. 1B). Notably, when these mice were treated with capsazepine, lung COX-2 activity levels were significantly alleviated (Fig. 1B). Furthermore, inhibition of endogenous H$_2$S formation by prophylactic or therapeutic administration of PAG markedly suppressed lung COX-2 expression (Fig. 2A) and activity (Fig. 2B) in untreated septic mice. Treatment of capsazepine in the same mice, however, did not significantly change the levels of PAG-mediated attenuation of COX-2 expression (Fig. 2A) and activity (Fig. 2B) in sepsis.
The H$_2$S-augmented, TRPV1-dependent COX-2 response correlates with concurrent PGEM production following septic injury

The observed increases in lung COX-2 levels lead us to examine lung PGE$_2$ levels post-septic injury. PGE$_2$ is known to be rapidly metabolized in vivo to its 13, 14-dihydro-15-keto metabolite; therefore, intact PGE$_2$ in tissues obtained from whole animals are scarce (32–34). For this reason, measurement of PGE$_2$ is necessary to provide a reliable estimate of actual PGE$_2$ production (35–37). In this study, lung PGE$_2$ levels were significantly increased in septic mice as compared with sham mice (Fig. 3A). The production of PGEM was further enhanced when exogenous NaHS was administered (Fig. 3A). Importantly, treatment with capsazepine abrogated lung PGEM levels in these mice (Fig. 3A). Blockade of endogenous H$_2$S synthesis further substantiated the inflammatory role of H$_2$S in sepsis, with PAG-treated septic mice showing marked alleviation in PGEM levels, and demonstrated that this reduction in PGEM production remained unchanged in the presence of capsazepine (Fig. 3B).

COX-2 inhibition prevents H$_2$S from aggravating ALI in sepsis

The clinical pathology of ALI is characterized by pulmonary edema, neutrophil infiltration with hemorrhage, and increased production of inflammatory mediators (3). Therefore, to assess the severity of COX-2-mediated ALI in sepsis, we examined the effect of a potent and selective COX-2 inhibitor, parecoxib, on lung MPO activity, which is an important index of neutrophil sequestration, and lung wet-to-dry weight ratio to determine the levels of pulmonary edema as well as histopathological examination of lung tissues to investigate the severity of lung injury. Results from MPO activity revealed significant lung neutrophil sequestration in septic mice as compared with sham controls, and this increment was further augmented in septic mice administrated with NaHS (Fig. 4A). Notably, these effects were markedly attenuated by parecoxib (Fig. 4A). Histologically, septic mice displayed characteristic signs of ALI, which included alveolar congestion, inflammatory cell infiltration, hemorrhage, septal thickening, and interstitial edema (Fig. 4B1, B3). Restoration of normal lung histoarchitecture was observed in septic mice treated with parecoxib (Fig. 4, B4), as revealed in sham-operated mice (Fig. 4B1). Likewise, lung architecture in septic mice that received NaHS intervention was damaged more than CLP alone, with marked pulmonary congestion and intense inflammatory cellular infiltrates in the septa in addition to erythrocytes originating from ruptured capillary vessels in the lung tissues (Fig. 4B5). However, such aggravation of lung alterations was improved by parecoxib (Fig. 4B6). Consistent with MPO and histology results, septic mice showed elevated lung wet-to-dry weight ratio, whereas treatment with parecoxib to these mice significantly alleviated pulmonary edema (Fig. 4C). Additionally, septic mice injected with NaHS demonstrated a further rise in lung wet-to-dry weight ratio compared with their vehicle control counterparts, which was again lowered with parecoxib intervention (Fig. 4C).

Blockade of H$_2$S-mediated activation of COX-2 impaired proinflammatory cytokine, chemokine, and adhesion molecule production in sepsis-evoked ALI

Septic mice showed a marked rise in lung proinflammatory cytokines TNF-α, IL-1β, IL-6, chemokines MIP-1α and MIP-2 (Fig. 5A–E), and adhesion molecules P-selectin, E-selectin, VCAM-1, and ICAM-1 (Fig. 6A–D) compared with sham mice. All of these were significantly reduced by parecoxib (Figs. 5, 6). Administration of NaHS in septic mice further enhanced the production of the aforementioned cytokines, chemokines, and adhesion molecules (Figs. 5, 6). Notably, all of their levels were greatly lowered upon treatment with parecoxib (Figs. 5, 6).

Inhibition of COX-2 attenuates H$_2$S-augmented PGEM production in septic lungs

Further evidence of lung protection by COX-2 inhibition was determined by measuring the levels of PGEM in the presence of parecoxib. As expected, lung PGEM levels were significantly increased following septic injury; however, parecoxib significantly decreased PGEM production in septic lungs (Fig. 7). Consistently, blockade of COX-2 with parecoxib drastically reduced PGEM production in septic lungs even in the presence of NaHS compared with the heightened levels detected in NaHS-injected septic mice (Fig. 7).

Inhibition of COX-2 protects against H$_2$S-augmented CLP-induced lethality, but has no effect on PAG-mediated protection of mortality in sepsis

Because the current study has proposed a key role of H$_2$S-augmented COX-2 response in sepsis-evoked ALI, it is imperative to investigate whether COX-2 inhibition would influence the late-phase events of sepsis, such as CLP-induced death. Our results revealed that mice subjected to CLP-induced sepsis displayed 0% survival by day 4 as compared with sham mice that were found normal with 100% survival throughout the 12-d study.
Administration of NaHS further worsened sepsis-associated mortality, with septic mice receiving NaHS intervention showing a drastic drop in survival rate that accounted for 0% at day 3 in comparison with their vehicle control counterparts that showed delayed survival for an additional 24 h (Fig. 8B). Importantly, parecoxib greatly improved survival in both septic and septic mice administered with NaHS, as evidenced by survival rates of 35 and 25%, respectively, in both instances (Fig. 8A, 8B). Additionally, we found that both prophylactic and therapeutic PAG decreased mortality significantly for up to 35–45% throughout the 12-d study period as compared with saline-injected septic mice that exhibited 0% survival on day 4 (Fig. 8C, 8D). However, survival rate in septic mice treated with both PAG and parecoxib was similar to those that were administrated with PAG and saline (Fig. 8C, 8D).

Discussion

Sepsis and its associated multiorgan failure remain a challenging global healthcare problem for both scientists and clinicians even in the modern era of critical care management. Severe sepsis, when accompanied by respiratory failure such as ALI or ARDS, continues to plague intensive care units with high mortality that has remained >40% (1, 2). Thus, identification of endogenous inflammatory molecules that mediate inflammation and injury of this often lethal complication of common human maladies represents an important goal with immediate diagnostic and therapeutic significance. Previously, we showed that the endogenously produced H2S by liver CSE, the major cell types responsible for H2S formation, promotes TRPV1-mediated neurogenic inflammation in polymicrobial sepsis (6). In this study, we report for the first time, to our knowledge, that H2S upregulates COX-2 and PGEM in sepsis through TRPV1 channel activation and that COX-2 inhibition with parecoxib, a potent and selective COX-2 inhibitor, prevents H2S from exacerbating ALI and CLP-induced mortality in sepsis.

PGE2 is largely thought to be synthesized from arachidonic acid via the actions of COX-2. It is known that >90% of circulating PGE2 is rapidly catabolized to inactive forms on the first pass in the lungs (33, 34, 38). Therefore, studies have used the measurement of PGEM as a common alternative to indicate the levels of PGE2 (35, 36, 39, 40). Results clearly demonstrate that induction of sepsis by CLP resulted in a concomitant and significant overproduction of COX-2 and PGEM in the lungs. Administration of NaHS further enhanced the biosynthesis of COX-2 and PGEM, whereas PAG significantly decreased these levels. Although hepatic CSE activity and plasma H2S level have been reported to be increased in CLP-induced sepsis (6), the usage of two different yet complementary approaches in this work—exogenous administration of NaHS that serves as an H2S donor and inhibition of yet complementary approaches in this work—exogenous administration of NaHS that serves as an H2S donor and inhibition of COX-2 and PGEM response but had no effect on PAG-mediated attenuation of both parameters in septic lungs, we ascertained

FIGURE 4. Inhibitory effects of parecoxib on lung MPO activity (A), histopathological evaluation (H&E staining) of lung polymorphonuclear leukocyte infiltration and injury (B), and pulmonary edema (C) in sepsis. Mice were randomly given NaHS (10 mg/kg i.p.) at the same time as CLP and parecoxib (30 mg/kg i.v.) or saline 20 min after CLP. Sham mice served as controls. Eight hours after CLP or sham operation, lung MPO activity, histopathological evaluation, and edema were assessed. Values are means ± SEM (n = 8–10 mice per group for MPO activity and histopathological evaluation and n = 10–15 mice per group for pulmonary edema). Lung sections: sham (B1), CLP (B2), CLP + saline (B3), CLP + parecoxib (B4), CLP + NaHS + saline (B5), and CLP + NaHS + parecoxib (B6). Objective lens magnification ×20; eyepiece magnification ×10. **p < 0.01 versus sham, ***p < 0.01 versus CLP + saline, †p < 0.05 versus CLP + saline, ‡p < 0.01 versus CLP + NaHS + saline.

Downloaded from http://www.jimmunol.org/ by guest on April 20, 2017
from our data that sepsis has a significant sensory neurogenic component that is mediated by H₂S in a TRPV1-dependent manner and that H₂S stimulation of TRPV1 occurs upstream of COX-2 and PGEM in sepsis.

More importantly, we were interested to know whether the H₂S-augmented, TRPV1-dependent COX-2 response can induce the production of PGEM and work in conjunction with it to incite remote ALI post-septic injury. To test this hypothesis, parecoxib, a water-soluble prodrug of valdecoxib and the first COX-2–specific inhibitor used for parenteral administration (26, 27), was employed. Notably, parecoxib exerts no deleterious effects on homeostatic functions mediated by COX-1 activation at therapeutic doses in the stomach and blood (25). Our results reveal that COX-2 inhibition with parecoxib significantly attenuated pulmonary neutrophil infiltration, edema formation, production of inflammatory cytokines, chemokines, and adhesion molecules, as well as restored lung histarchitecture in sepsis, thereby significantly prevented the development of sepsis-evoked ALI. Moreover, the fact that exogenous administration of NaHS to septic mice showed exacerbated ALI compared with mice subjected to CLP alone and that these pathophysiologic consequences of ALI were significantly abrogated upon treatment with parecoxib confirm the notion that sepsis-evoked ALI was specifically attributable to the interplay between H₂S and COX-2. Intrigued by the strong inhibitory effects of parecoxib on H₂S-induced inflammation and injury in the lungs of septic mice, our results also suggest that selective blockade of COX-2 could constitute an important therapeutic target for the treatment of sepsis-evoked ALI.

FIGURE 5. Inhibitory effects of parecoxib on heightened expressions of proinflammatory cytokines and chemokines in septic lungs. Mice were randomly given NaHS (10 mg/kg i.p.) at the same time as CLP and parecoxib (30 mg/kg i.v.) or saline 20 min after CLP. Sham mice served as controls. Eight hours after CLP or sham operation, lung levels of TNF-α (A), IL-1β (B), IL-6 (C), MIP-1α (D), and MIP-2 (E) were measured. Values are means ± SEM (n = 8–10 mice per group). *p < 0.01 versus sham, **p < 0.01 versus CLP + saline, ‡p < 0.01 versus CLP + NaHS + saline.
A number of studies have suggested a significant role for COX-2 in the development of ALI (9, 10). Specifically, COX-2 levels increased concomitantly with the severity of ALI, whereas inhibition of COX-2 attenuated ALI in an acid aspiration-induced model of ALI and carrageenan-induced pleurisy model in rats (9, 43). In addition, PGE2 has been shown to be heightened in both animal models of endotoxin shock and clinical cases of sepsis (22, 44). It has been shown to exert significant immune system dysfunction in sepsis, such as vasodilation, increased vascular permeability, and generation of local and systemic inflammatory response (45). Furthermore, it has been reported that inhibition of COX restored immune alterations and improved survival caused by sepsis (13). In agreement with these findings, our results reveal marked attenuation of lung PGE levels in both septic and septic mice administrated with NaHS upon treatment with parecoxib as compared with the elevated levels observed in the same mice without parecoxib. These observations not only support the findings that the induction of COX-2 by H2S can translate into increased production of PGE2, but also validate the use of parecoxib as a COX-2 inhibitor.

Of even greater significance, results from our work provide convincing evidence demonstrating that the H2S induction of the COX-2/PGE2 pathway is a critical component of the lethal response associated with CLP-induced sepsis in mice. Our previous studies have reported that exogenous application of NaHS to septic mice further worsened, whereas blockade of endogenous H2S synthesis by PAG protected against organ injury and death in sepsis (6). In this study, we report that inhibition of COX-2 significantly protected against sepsis-associated mortality, as reflected by prolonged survival seen in both septic and NaHS-injected septic mice that received parecoxib intervention. Consistent with these findings, absence of COX-2 rendered COX-2–deficient mice resistant to endotoxin-induced inflammation and lethality (11). Besides, our data reveal that both prophylactic and therapeutic PAG decreased mortality significantly for up to 35–45% throughout the 12-d study period. However, survival rate was not significantly different in mice treated with both PAG and parecoxib when compared with those treated with PAG only, suggesting that the improved survival rate in sepsis was likely associated with blockade of H2S synthesis. Once formation of
endogenously produced H2S is inhibited, H2S is unable to elicit
the downstream activation of TRPV1 and the subsequent upregu-
lation of COX-2/PGE2 in sepsis. Hence, the presence or absence
of COX-2 inhibition with parecoxib does not make a difference.

Cross talk between H2S and SP raises another possible way
that H2S may upregulate COX-2 and PGEM in sepsis indirectly
through the effects of SP. Indeed, several studies highlighted the
significance of SP and COX-2 in various inflammatory states (14–
17). Particularly, SP has been demonstrated to stimulate COX-2
and PGEM upregulation through the ERK–NF-kB pathway in
murine burn-induced remote ALI (14). SP was also demonstrated
to augment PGE2 production in lyme disease-associated inflam-
matory conditions in murine microglia (46) and to induce COX-2
expression and NF-kB activation in human polymorphonuclear
leukocytes (16). Furthermore, SP incites COX-2 and PGE2 ex-
pression in human colonic epithelial cells and HUVECs through
the activation of JAK–STAT (15) and MAPK pathways (17), re-
spectively. Given that endogenous H2S was known to upregulate
SP in sepsis-induced ALI (47) and to regulate inflammatory re-
sponse in CLP-induced sepsis by activating the ERK1/2 and NF-
kB pathways (42), there exists the possibility that H2S may con-
tribute to sepsis-evoked ALI via the signal transduction pathway
of H2S–TRPV1–NF-kB–COX-2–PGEM. Although the exact mechanistic pathway mediating H2S induction of COX-2
remains to be investigated, H2S and SP may share a common
signaling cascade involving the activation of ERK and NF-kB.
Yet, they may also contribute to COX-2/PGE2 response in-
dependent of each other because SP has been shown to upregulate
COX-2 and PGE2 through other signaling mechanisms.

Even though our findings indicate that COX-2 and PGE2
function as proinflammatory mediators in sepsis-associated ALI,
some investigators have reported a protective role for COX-2 and
PGE2 following experimental lung injury (48–50). The discrep-
ancy may be determined by many factors, including the exact
nature of the stimulus, the specific cell type involved in their
production, the blend of specific surface and intracellular recep-
tors that mediate diverse cellular events, and their differential
coupling to signal transduction pathways. Furthermore, PGE2
exerts both pro- and anti-inflammatory effects depending on re-
ceptor subtypes, cell population, and context of activation (51,
52). It has been reported that PGE2 inhibits the production of
cytokines like TNF-α in macrophages through the PG receptor
termed E prostanoid (EP) 4 and T cell proliferation through the
EP2 receptor and thus would be anti-inflammatory (53). In con-
trast, activation of EP3 receptor by PGE2 has been identified as
having a proinflammatory stimulus in ALI because it was involved
in the development of pulmonary edema (54). Additionally, the
profiles of COX-2–derived PG generated in an inflammatory site
change during the course of inflammation as a result of lipid
mediator class switching (55). PG released during the acute phase
of inflammation, notably PGE2, is proinflammatory, whereas
those made in the late (resolution) phase are dominated by
PGF2α, PGD2, and cyclopentenone PG, which exert anti-inflam-
matory effects (51). It is believed that increased levels of these
endogenous proresolving mediators override the proinflammatory
actions of PGE2, shifting the overall balance favoring the pro-
resolving homeostatic mechanisms in the lung (51, 52). Further-
more, COX-2–derived PGE2 is known to mediate the formation of
lipoxins, a family of potent anti-inflammatory lipid mediators, in
the late phase of acute inflammation (55, 56). In a murine model
of acid-initiated ALI, COX-2 has been implicated to hasten res-
olution of lung inflammation and injury, in part by promoting the

**FIGURE 8.** Effect of parecoxib on CLP-induced mortality in septic mice (A), septic mice injected with NaHS (B), septic mice receiving prophylactic
PAG (C), and septic mice receiving therapeutic PAG (D). Mice were randomly given NaHS (10 mg/kg i.p.) at the same time as CLP or PAG (50 mg/kg i.p.)
1 h before (Prophylactic) or 1 h after (Therapeutic) CLP and parecoxib (30 mg/kg i.v.) or saline 20 min after CLP. Sham mice served as controls. Survival
was monitored every 24 h for up to 12 d. Results are expressed as survival rate (n = 15–20 mice per group). Significant differences are shown in the figure.
endogenous formation of lipoxin A4 and 15-epi-lipoxin A4 (49). Injured human bronchial epithelial cells have also been demonstrated to promote lipoxin A4-mediated resolution of acid-triggered airway inflammation in a COX-2–dependent manner (50). Similarly, lipoxin A4 has been proposed to be a possible protective factor in COX-2–regulated lung protection in splanchic ischemia/reperfusion-mediated ALI (48). Collectively, these studies suggest that COX-2 may have biphasic and opposing roles in the pathophysiology of inflammation in ALI, an early proinflammatory effect and a later proresolving action. Our work, which focused on the acute events of lung inflammation and injury in sepsis, reconciled with the published findings concerning the initial, proinflammatory phenotype of COX-2 in the inflammation–resolution pathway of ALI.

In conclusion, we report for the first time, to our knowledge, that H2S augments the upregulation of COX-2 and PGEM, which orchestrates the neurogenic inflammatory response via activation of TRPV1 channel, and consequently contributes to lung inflammation and injury in a mouse model of sepsis-induced ALI. Additionally, inhibition of the COX-2/PGE2 pathway in the septic lungs significantly ameliorates inflammation, injury, and sepsis-associated mortality, thereby providing a potential therapeutic approach for the prevention of ALI in sepsis.

Disclosures

The authors have no financial conflicts of interest.

References


